Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines how GLP-1 receptor agonists might impact metabolic and reproductive outcomes in polycystic ovary syndrome, but it reports no new clinical findings and highlights the need for further research.

This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.

GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.

In this study, patient-reported outcomes indicated that greater weight loss with GLP-1RA treatments was associated with increased reports of adverse cosmetic effects such as skin laxity, facial volume loss, and hair shedding, despite improvements in some preexisting inflammatory skin conditions.

This study observed that dermatological and hair changes, like skin sagging and hair shedding, commonly occur early during weight loss with GLP-1 receptor agonists, highlighting the need for tailored dermatological care alongside treatment.

This review suggests weak associations between GLP-1 receptor agonists and increased reports of hair loss, particularly with semaglutide and tirzepatide, while cases of hair regrowth were also occasionally documented.

This systematic review found conflicting evidence on hair loss related to GLP-1 receptor agonists in adults with type 2 diabetes or obesity, with some studies noting hair regrowth and others reporting hair loss as a side effect. Further research is needed to understand this relationship.

This review highlights concerns about dermatological side effects linked to rapid weight loss from glucagon-like peptide-1 receptor agonists used for type 2 diabetes and obesity treatment, such as skin laxity, decreased collagen, and hair loss, emphasizing the importance of managing these while retaining metabolic benefits.

This study found that GLP-1 receptor agonists are linked to a 40% increased risk of non-scarring alopecia in adults, mainly due to weight loss-induced micronutrient deficiencies, with semaglutide and tirzepatide showing the highest hair loss signals.

This study found that GLP-1 receptor agonists are linked to a significant 40% increased risk of non-scarring alopecia, which may result from weight loss-induced micronutrient deficiency.

This editorial examines how GLP-1 receptor agonists, providing significant weight loss and cardiovascular benefits, can be integrated into a comprehensive obesity treatment alongside diet and lifestyle changes, but highlights the need for further guidance on their real-world application and multidisciplinary care.

This review suggests that glucagon-like peptide 1 receptor agonists may play a potentially protective role in managing diabetic foot ulcers, particularly by addressing various underlying pathophysiological aspects.

This review summarizes recent research into the effects of GLP-1 receptor agonists on skin processes, noting potential benefits for wound healing but also potential cosmetic concerns like facial fat loss and decreased collagen, highlighting the need for more clinical studies to clarify their dermatological impact.

This study found that patients using GLP-1 receptor agonists, specifically liraglutide, dulaglutide, and semaglutide, had a higher likelihood of being diagnosed with androgenetic alopecia, while those on exenatide showed increased odds for both androgenetic alopecia and telogen effluvium.

This review suggests that GLP-1 receptor agonists may improve various dermatologic conditions, but larger studies are needed to confirm these findings.

This review indicates that glucagon-like peptide-1 receptor agonists may be linked to hair loss, raising safety concerns despite the lack of definitive causal evidence.

This study provides a narrative review suggesting GLP-1 receptor agonists could optimize metabolic health before conception in women with PCOS, but not necessarily improve fertility outcomes, emphasizing individualized use and the need for further research to confirm their reproductive benefits and safety.

This narrative review explores current evidence on GLP-1 receptor agonists and hair-related conditions, noting reports of both hair regrowth and potential associations with telogen effluvium.

GLP-1 RA medications may be linked to hair loss.

In this study, GLP-1 receptor agonists reduced BMI and improved metabolic and reproductive outcomes in women with PCOS, though the long-term effects remain unclear.

This publication discusses the 2021 ESC Guidelines for the prevention of cardiovascular disease in clinical practice and reports no new results.

This review found no evidence that medications used to manage PCOS add to cardiovascular risk or prevent diabetes onset, although metformin may help prevent gestational diabetes in these patients.

This review suggests that, among non-hormonal treatments for menstrual irregularities in adolescents with PCOS, metformin is the most effective and cost-efficient option, particularly in overweight adolescent girls.

This study found that glucagon-like peptide-1 receptor agonist therapy was independently associated with an increased incidence of non-scarring hair loss, including telogen effluvium and androgenic alopecia, in adults but not alopecia areata.

This literature review highlights a potential but uncertain link between GLP-1 receptor agonist therapy for type 2 diabetes and obesity and hair loss, with variations among different medications.

In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.

This study reports conflicting evidence on whether GLP-1 receptor agonists are associated with various forms of alopecia, suggesting dermatology practitioners should consider monitoring and counseling patients using these medications.

This study reviews current treatments for PCOS and evaluates Tirzepatide as a potential option for its management, suggesting possible benefits for those with obesity and metabolic syndrome but not for those of normal weight.

This review discusses current pharmacological and non-pharmacological treatment strategies for PCOS, emphasizing the need for a personalized, multimodal approach due to incomplete understanding of the syndrome's pathogenesis.

This study observed that methylene blue, a mitochondrial-targeted antioxidant, promotes hair follicle stem cell proliferation and viability through reduced oxidative stress and enhanced β-catenin signaling, and it may also protect against hair loss related to glucagon-like peptide-1 receptor agonists by reducing metabolic stress.